The presence of the p53 transcripts with truncated open reading frames in Marek's disease tumor-derived cell lines

Leukemia Research

Volumn 30, Issue 8, 2006, Pages 987-992

  Takagi, Michihiro ^a   Ohashi, Kazuhiko ^b   Morimura, Toshifumi ^b   Sugimoto, Chihiro ^c   Onuma, Misao ^b  

^a KOBE UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

Author keywords

Marek's disease; p53; RT PCR

Indexed keywords

ISOPROTEIN; MONOCLONAL ANTIBODY; PROLINE; PROTEIN P53; VIRUS T ANTIGEN;

ANIMAL CELL; ARTICLE; BIRD DISEASE; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; FRAMESHIFT MUTATION; GENE DELETION; GENETIC TRANSCRIPTION; MOLECULAR WEIGHT; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RETICULOENDOTHELIOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; HUMANS; MAREK DISEASE; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33744799714     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.12.009     Document Type: Article

References (47)

1. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
2. Balint E.E., and Vousden K.H. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 85 (2001) 1813-1823
3. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2 (2002) 594-604
4. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., and Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1 (1992) 45-49
5. Okamoto K., and Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 13 (1994) 4816-4822
6. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
7. Barak Y., Juven T., Haffne R., and Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 12 (1993) 461-468
8. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71 (1992) 587-597
9. Caelles C., Helmberg A., and Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370 (1994) 220-223
10. Kokontis J.M., Wagner A.J., O'Leary M., Liao S., and Hay N. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. Oncogene 20 (2001) 659-668
11. Giaccia A.J., and Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12 (1998) 2973-2983
12. Soussi T., and Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1 (2001) 233-240
13. Benard J., Douc-Rasy S., and Ahomadegbe J.C. TP53 family members and human cancers. Hum Mutat 21 (2003) 182-191
14. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 Mutations in human cancers. Science 253 (1991) 49-53
15. Holmila R., Fouquet C., Cadranel J., Zalcman G., and Soussi T. Spliced mutations in the p53 gene: case report and review of the literature. Hum Mutat 21 (2003) 101-102
16. Collot-Teixeira S., Bass J., Denis F., and Ranger-Rogez S. Human tumor suppressor p53 and DNA viruses. Rev Med Virol 14 (2004) 301-319
17. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., et al. Integration of interferon-a signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (2003) 516-523
18. Schat K.A. Marek's disease: a model for protection against herpesvirus-induced tumors. Cancer Surv 6 (1987) 1-37
19. Gimeno I.M., Witter R.L., Fadly A.M., and Silva R.F. Novel criteria for the diagnosis of Marek's disease virus-induced lymphoma. Avian Pathol 34 (2005) 332-340
20. Kung H.-J., Xia L., Brunovskis P., Li D., Liu J.-L., and Lee L.F. Meq: an MDV-specific bZIP transactivator with transforming properties. Curr Opin Microbiol Immunol 255 (2000) 245-260
21. Liu J.-L., Ye Y., Lee L.F., and Kung H.-J. Transforming potential of the herpesvirus oncoprotein MEQ: morphological transformation, serum-independent growth, and inhibition of apoptosis. J Virol 72 (1998) 388-395
22. Jones D., Lee L., Liu J.-L., Kung H.-J., and Tillotson J.K. Marek's disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors. Proc Natl Acad Sci USA 89 (1992) 4042-4046
23. Xie Q., Anderson A.S., and Morgan R.W. Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells. J Virol 70 (1996) 1125-1131
24. Brunovskis P., Qian Z., Li D., Lee L.F., and Kung H.-J. Functional analysis of the MDV basic-leucine zipper product, meq. In: Silva R.F., Cheng H.H., Coussens P.M., Lee L.F., and Velicer L.F. (Eds). Current research on Marek's disease (1996), American Association of Avian Pathologists, Kennett Square 265-270
25. Takagi M., Ohashi K., Morimura T., Sugimoto C., and Onuma M. Analysis of tumor suppressor gene p53 in chicken lymphoblastoid tumor cell lines and field tumors. J Vet Med Sci 60 (1998) 923-929
26. Akiyama Y., and Kato S. Two cell lines from lymphomas of Marek's disease. Biken J 17 (1974) 105-116
27. Ikuta K., Nakajima K., Kanamori A., Maotani K., Mah J.S., Ueda S., et al. Establishment and characterization of a T-lymphoblastoid cell line MDCC-MTB1 derived from chicken lymphocytes infected in vitro with Marek's disease virus serotype I. Int J Cancer 39 (1985) 514-520
28. K of B blood groups. Biken J 22 (1979) 35-40
29. Powell P.C., Payne L.N., Frazier J.A., and Rennie M. T lymphoblastoid cell lines from Marek's disease lymphomas. Nature 251 (1974) 79-80
30. Nazerian K., Stephens E.A., Sharma J.M., Lee L.F., Gailitis M., and Witter R.L. A nonproducer T lymphoblastoid cell line from Marek's disease transplantable tumor (JMV). Avian Dis 21 (1976) 69-76
31. Hihara H., Shimizu T., and Yamamoto H. Establishment of tumor cell lines cultured from chickens with avian lymphoid leucosis. Natl Inst Anim Health Q 14 (1974) 163-173
32. Calnek B.W., Murthy K.K., and Schat K.A. Establishment of Marek's disease lymphoblastoid cell lines from transplantable versus primary lymphoma. Int J Cancer 21 (1978) 100-107
33. Sasaki T., Koyama H., Yoshikawa H., and Sasahara J. Establishment of tumor cell lines cultured from chick embryos and chickens inoculated with oncogenic reticuloendotheliosis virus. Proceedings of the 92nd meeting of Japan society veterinary science (1981) 170
34. Soussi T., Caron de Fromentel C., and May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5 (1990) 945-952
35. Legros Y., Meyer A., Ory K., and Soussi T. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene 9 (1994) 3689-3694
36. Gannon J.V., Greaves R., Iggo R., and Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9 (1990) 1595-1602
37. Han K.A., and Kulesz-Martin M.F. Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nucl. Acids Res 20 (1992) 1979-1981
38. Kulesz-Martin M.F., Lisafeld B., Huang H., Kisiel N.D., and Lee L. Endogenous p53 protein generated from wild type alternatively spliced p53 RNA in mouse epidermal cells. Mol Cell Biol 14 (1994) 1698-1708
39. Flaman J.M., Waridel F., Estereicher A., Vannier A., Limacher J.M., Gilbert D., et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12 (1996) 813-818
40. Laverdiere M., Beaudoin J., and Lavigueur A. Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. Nucl. Acid Res 28 (2000) 1489-1497
41. Ghosh A., Stewart D., and Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24 (2004) 7987-7997
42. Rohaly G., Chemnitz J., Dehde S., Nunez A.M., Heukeshoven J., Deppert W., et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 122 (2005) 21-32
43. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valnet A., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
44. De Laurenzi V., Costanzo A., Barcaroli D., Terrinoni A., Falco M., Annicchiarico-Petruzzelli M., et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188 (1998) 1763-1768
45. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., et al. p63, a p53 Homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2 (1998) 305-316
46. Almog N., Goldfinger N., and Rotter V. p53-Dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53. Oncogene 19 (2000) 3395-3403
47. Schat K.A., Buckmaster A., and Ross L.J. Partial transcription map of Marek's disease herpesvirus in lytically infected cells and lymphoblastoid cell lines. Int J Cancer 44 (1989) 101-109